drugset

drugset / Trial / NCT01111903

A 2 Stage Trial of Lenalidomide (REV) in Asymptomatic Ovarian Cancer Patients With Increasing CA 125 in Late Relapse

NCT01111903 ↗

Phase 1/2 Completed 67 enrolled ARCAGY/ GINECO GROUP

NaSingle-groupOpen-labelTreatment

Summary

Study in two stages, and with a sub-study.

Timeline

Start: 2009-05
Primary completion: 2014-12
Completion: 2014-12

Publications

Selle F, Sevin E, Ray-Coquard I, Mari V, Berton-Rigaud D, Favier L, Fabbro M, Lesoin A, Lortholary A, Pujade-Lauraine E. A phase II study of lenalidomide in platinum-sensitive recurrent ovarian carcinoma. Ann Oncol. 2014 Nov;25(11):2191-2196. doi: 10.1093/annonc/mdu392. Epub 2014 Sep 10.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Lenalidomide	Other / unclassified	20 mg	Oral
Subject	Lenalidomide	Other / unclassified	25 mg	Oral

Indications